Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

Pharmacology and Therapeutics

Volumn 140, Issue 2, 2013, Pages 156-166

  Konstantinou, Dimitrios M ^a,b   Chatzizisis, Yiannis S ^a,c   Giannoglou, George D ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diastolic dysfunction; Heart failure; Pathophysiology; Pharmacotherapy

Indexed keywords

2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE ANTAGONIST; ALISKIREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; EXENDIN 4; LOSARTAN; NITRIC OXIDE; OMAPATRILAT; PHOSPHODIESTERASE V INHIBITOR; PIOGLITAZONE; RANOLAZINE; ROSIGLITAZONE; SILDENAFIL; SITAGLIPTIN; SPIRONOLACTONE; TETRAHYDROBIOPTERIN; VALSARTAN;

DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; ENERGY TRANSFER; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM CURRENT; TREATMENT OUTCOME;

ACEI; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; ANGIOTENSIN II RECEPTOR BLOCKERS; ANP; ARBS; ATRIAL NATRIURETIC PEPTIDE; BH4; BNP; BRAIN NATRIURETIC PEPTIDE; CAMP; CGMP; CYCLIC ADENOSINE MONOPHOSPHATE; CYCLIC GUANOSINE MONOPHOSPHATE; DIASTOLIC DYSFUNCTION; DIPEPTIDYL-PEPTIDASE; DPP; GC; GLP-1; GLUCAGON LIKE PEPTIDE-1; GUANYLATE CYCLASE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HFPEF; HFREF; LATE I(NA); LATE NA(+) CURRENT; NA(+)-CA(2+) EXCHANGER; NCX; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NO; NOS; PATHOPHYSIOLOGY; PDE; PHARMACOTHERAPY; PHOSPHODIESTERASES; PKA; PKG; PROTEIN KINASE A; PROTEIN KINASE G; RAAS; RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM; RYANODINE RECEPTOR-2; RYR2; SARCOPLASMIC RETICULUM CA(++) ATPASE-ISOFORM 2; SERCA2; TETRAHYDROBIOPTERIN; TGF-Β1; TRANSFORMING GROWTH FACTOR-Β1;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84885173589     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.05.012     Document Type: Review

References (119)

1. E.D. Abel, S.E. Litwin, and G. Sweeney Cardiac remodeling in obesity Physiol Rev 88 2008 389 419
2. D. Abramov, K.L. He, J. Wang, D. Burkhoff, and M.S. Maurer The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction J Card Fail 17 2011 547 555
3. M.S. Alkaitis, and M.J. Crabtree Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling Curr Heart Fail Rep 9 2012 200 210
4. M.J. Andersen, M. Ersboll, A. Axelsson, F. Gustafsson, C. Hassager, and L. Kober Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial Circulation 127 2013 1200 1208
5. V.Y. Anjan, T.M. Loftus, M.A. Burke, N. Akhter, G.C. Fonarow, and M. Gheorghiade Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction Am J Cardiol 110 2012 870 876
6. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 116 2007 434 448
7. M.L. Bang, T. Centner, F. Fornoff, A.J. Geach, M. Gotthardt, and M. McNabb The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system Circ Res 89 2001 1065 1072
8. R.S. Bhatia, J.V. Tu, D.S. Lee, P.C. Austin, J. Fang, and A. Haouzi Outcome of heart failure with preserved ejection fraction in a population-based study N Engl J Med 355 2006 260 269
9. K.R. Bidasee, K. Nallani, Y. Yu, R.R. Cocklin, Y. Zhang, and M. Wang Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels Diabetes 52 2003 1825 1836
10. B.A. Borlaug, and W.J. Paulus Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 2011 670 679
11. C.M. Carlsen, M. Bay, V. Kirk, J.P. Gotze, L. Kober, and O.W. Nielsen Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study Eur J Heart Fail 14 2012 240 247
12. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
13. V.M. Conraads, M. Metra, O. Kamp, G.W. De Keulenaer, B. Pieske, and J. Zamorano Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study Eur J Heart Fail 14 2012 219 225
14. S. Currie, E.B. Elliott, G.L. Smith, and C.M. Loughrey Two candidates at the heart of dysfunction: the ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention - an in vivo perspective Pharmacol Ther 131 2011 204 220
15. S. Daff NO synthase: structures and mechanisms Nitric Oxide 23 2010 1 11
16. K.R. Daniel, G. Wells, K. Stewart, B. Moore, and D.W. Kitzman Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure Congest Heart Fail 15 2009 68 74
17. M. Diamant, and R.J. Heine Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence Drugs 63 2003 1373 1405
18. M. Diamant, H.J. Lamb, Y. Groeneveld, E.L. Endert, J.W. Smit, and J.J. Bax Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus J Am Coll Cardiol 42 2003 328 335
19. U.D. Dincer Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy? Diabetes Metab Syndr Obes 5 2012 89 99
20. U.D. Dincer, A. Araiza, J.D. Knudson, C.H. Shao, K.R. Bidasee, and J.D. Tune Dysfunction of cardiac ryanodine receptors in the metabolic syndrome J Mol Cell Cardiol 41 2006 108 114
21. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, and I.K. Moules Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
22. D.J. Drucker Glucagon-like peptides Diabetes 47 1998 159 169
23. F. Edelmann, R. Wachter, A.G. Schmidt, E. Kraigher-Krainer, C. Colantonio, and W. Kamke Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial J Am Med Assoc 309 2013 781 791
24. I. Falcao-Pires, and A.F. Leite-Moreira Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment Heart Fail Rev 17 2012 325 344
25. V.M. Figueredo, G.S. Pressman, A. Romero-Corral, E. Murdock, P. Holderbach, and D.L. Morris Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina J Cardiovasc Pharmacol Ther 16 2011 168 172
26. R. Fischer, R. Dechend, F. Qadri, M. Markovic, S. Feldt, and F. Herse Dietary n - 3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension Hypertension 51 2008 540 546
27. G.C. Fonarow, W.G. Stough, W.T. Abraham, N.M. Albert, M. Gheorghiade, and B.H. Greenberg Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 2007 768 777
28. S. Ghio, G. Magrini, A. Serio, C. Klersy, A. Fucili, and A. Ronaszeki Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy Eur Heart J 27 2006 562 568
29. E. Giannetta, A.M. Isidori, N. Galea, I. Carbone, E. Mandosi, and C.D. Vizza Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging Circulation 125 2012 2323 2333
30. A.H. Gradman, R.E. Schmieder, R.L. Lins, J. Nussberger, Y. Chiang, and M.P. Bedigian Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 2005 1012 1018
31. H. Granzier, and S. Labeit Cardiac titin: an adjustable multi-functional spring J Physiol 541 2002 335 342
32. G. Grassi, R. Dell'Oro, F. Quarti-Trevano, F. Scopelliti, G. Seravalle, and F. Paleari Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome Diabetologia 48 2005 1359 1365
33. J. Gu, A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, and R. Sarangapani Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
34. M. Guazzi, M. Vicenzi, R. Arena, and M.D. Guazzi Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study Circulation 124 2011 164 174
35. R.I. Hamby, R.H. Weissman, M.N. Prakash, and I. Hoffman Left bundle branch block: a predictor of poor left ventricular function in coronary artery disease Am Heart J 106 1983 471 477
36. G. Hasenfuss, and B. Pieske Calcium cycling in congestive heart failure J Mol Cell Cardiol 34 2002 951 969
37. W. Hayashida, C. van Eyll, M.F. Rousseau, and H. Pouleur Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease Cardiovasc Drugs Ther 8 1994 741 747
38. A.F. Hernandez, B.G. Hammill, C.M. O'Connor, K.A. Schulman, L.H. Curtis, and G.C. Fonarow Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry J Am Coll Cardiol 53 2009 184 192
39. S. Heymans, B. Schroen, P. Vermeersch, H. Milting, F. Gao, and A. Kassner Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart Circulation 112 2005 1136 1144
40. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, and N.P. Jones Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 2007 28 38
41. S. Hsu, T. Nagayama, N. Koitabashi, M. Zhang, L. Zhou, and D. Bedja Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway Cardiovasc Res 81 2009 301 309
42. S.E. Inzucchi, and D.K. McGuire New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond Circulation 117 2008 574 584
43. 2+ exchanger type-1 in vascular smooth muscle Nat Med 10 2004 1193 1199
44. D. Kamimura, T. Ohtani, Y. Sakata, T. Mano, Y. Takeda, and S. Tamaki Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction Eur Heart J 33 2012 1408 1416
45. N. Kaneko, R. Matsuda, Y. Hata, and K. Shimamoto Pharmacological characteristics and clinical applications of K201 Curr Clin Pharmacol 4 2009 126 131
46. N. Kaneko, R. Matsuda, N. Ohtani, T. Nakajima, T. Arikawa, and H. Suzuki K201 Improves norepinephrine-induced diastolic dysfunction with preserved ejection fraction Drug Dev Res 67 2006 852 861
47. A. Kelly, E.B. Elliott, R. Matsuda, N. Kaneko, G.L. Smith, and C.M. Loughrey The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload Br J Pharmacol 165 2012 1068 1083
48. A.M. Khan, S. Cheng, M. Magnusson, M.G. Larson, C. Newton-Cheh, and E.L. McCabe Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies J Clin Endocrinol Metab 96 2011 3242 3249
49. M. Kim, J.K. Paik, R. Kang, S.Y. Kim, S.H. Lee, and J.H. Lee Increased oxidative stress in normal-weight postmenopausal women with metabolic syndrome compared with metabolically healthy overweight/obese individuals Metabolism 62 2013 554 560
50. D.W. Kitzman, W.C. Little, P.H. Brubaker, R.T. Anderson, W.G. Hundley, and C.T. Marburger Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure J Am Med Assoc 288 2002 2144 2150
51. A. Kjaer, and B. Hesse Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives Clin Physiol 21 2001 661 672
52. W. Kosmala, M. Przewlocka-Kosmala, H. Szczepanik-Osadnik, A. Mysiak, T. O'Moore-Sullivan, and T.H. Marwick A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome JACC Cardiovasc Imaging 4 2011 1239 1249
53. J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, and E. Levy Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
54. M. Kruger, S. Kotter, A. Grutzner, P. Lang, C. Andresen, and M.M. Redfield Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs Circ Res 104 2009 87 94
55. V.A. Lacombe, S. Viatchenko-Karpinski, D. Terentyev, A. Sridhar, S. Emani, and J.D. Bonagura Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes Am J Physiol Regul Integr Comp Physiol 293 2007 R1787 R1797
56. H.J. Lamb, H.P. Beyerbacht, A. van der Laarse, B.C. Stoel, J. Doornbos, and E.E. van der Wall Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism Circulation 99 1999 2261 2267
57. J. Layland, J.M. Li, and A.M. Shah Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes J Physiol 540 2002 457 467
58. E.R. Levin, D.G. Gardner, and W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328
59. P. Li, D. Wang, J. Lucas, S. Oparil, D. Xing, and X. Cao Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts Circ Res 102 2008 185 192
60. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, and G. De Simone Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
61. A.M. Lompre, R.J. Hajjar, S.E. Harding, E.G. Kranias, M.J. Lohse, and A.R. Marks Ca2+ cycling and new therapeutic approaches for heart failure Circulation 121 2010 822 830
62. G.D. Lopaschuk, J.R. Ussher, C.D. Folmes, J.S. Jaswal, and W.C. Stanley Myocardial fatty acid metabolism in health and disease Physiol Rev 90 2010 207 258
63. J.D. Lovelock, M.M. Monasky, E.M. Jeong, H.A. Lardin, H. Liu, and B.G. Patel Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity Circ Res 110 2012 841 850
64. L.S. Maier, and D.M. Bers Calcium, calmodulin, and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond J Mol Cell Cardiol 34 2002 919 939
65. L.S. Maier, B. Layug, E. Karwatowska-Prokopczuk, L. Belardinelli, S. Lee, and J. Sander Ranolazine for the treatment of diastolic heart failure in patients with preserved Β ejection fraction: the RALI-DHF proof-of-concept study JACC Heart Fail 1 2013 115 122
66. V.A. Maltsev, N. Silverman, H.N. Sabbah, and A.I. Undrovinas Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability Eur J Heart Fail 9 2007 219 227
67. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, and M.R. Zile Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456 2467
68. M. Metra, S. Nodari, A. D'Aloia, A. Madureri, F. Rosselli, and L. Bontempi Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure Eur Heart J 19 Suppl. B 1998 B25 B35
69. V. Mitrovic, A.F. Hernandez, M. Meyer, and M. Gheorghiade Role of guanylate cyclase modulators in decompensated heart failure Heart Fail Rev 14 2009 309 319
70. A.L. Moens, E. Takimoto, C.G. Tocchetti, K. Chakir, D. Bedja, and G. Cormaci Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy Circulation 117 2008 2626 2636
71. S.F. Mohammed, B.A. Borlaug, V.L. Roger, S.A. Mirzoyev, R.J. Rodeheffer, and J.A. Chirinos Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study Circ Heart Fail 5 2012 710 719
72. A.J. Moss, W. Zareba, K.Q. Schwarz, S. Rosero, S. McNitt, and J.L. Robinson Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome J Cardiovasc Electrophysiol 19 2008 1289 1293
73. A. Mosterd, and A.W. Hoes Clinical epidemiology of heart failure Heart 93 2007 1137 1146
74. M. Movsesian, J. Stehlik, F. Vandeput, and M.R. Bristow Phosphodiesterase inhibition in heart failure Heart Fail Rev 14 2009 255 263
75. S.F. Nagueh, G. Shah, Y. Wu, G. Torre-Amione, N.M. King, and S. Lahmers Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy Circulation 110 2004 155 162
76. C. Neagoe, M. Kulke, F. del Monte, J.K. Gwathmey, P.P. de Tombe, and R.J. Hajjar Titin isoform switch in ischemic human heart disease Circulation 106 2002 1333 1341
77. T.E. Owan, D.O. Hodge, R.M. Herges, S.J. Jacobsen, V.L. Roger, and M.M. Redfield Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 2006 251 259
78. C. Palaniswamy, W.M. Mellana, D.R. Selvaraj, and D. Mohan Metabolic modulation: a new therapeutic target in treatment of heart failure Am J Ther 18 2011 e197 e201
79. H.H. Parving, B.M. Brenner, J.J. McMurray, D. de Zeeuw, S.M. Haffner, and S.D. Solomon Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 2009 1663 1671
80. K. Patel, G.C. Fonarow, D.W. Kitzman, I.B. Aban, T.E. Love, and R.M. Allman Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction JACC Heart Fail 1 2013 40 47
81. W.J. Paulus, C. Tschope, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, and F.E. Rademakers How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 28 2007 2539 2550
82. W.J. Paulus, and J.J. van Ballegoij Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 55 2010 526 537
83. T.T. Phan, K. Abozguia, G. Nallur Shivu, G. Mahadevan, I. Ahmed, and L. Williams Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency J Am Coll Cardiol 54 2009 402 409
84. B. Pilz, E. Shagdarsuren, M. Wellner, A. Fiebeler, R. Dechend, and P. Gratze Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats Hypertension 46 2005 569 576
85. P. Poirier, P. Bogaty, C. Garneau, L. Marois, and J.G. Dumesnil Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy Diabetes Care 24 2001 5 10
86. C.A. Reasner, and 2nd. Promising new approaches Diabetes Obes Metab 1 Suppl. 1 1999 S41 S48
87. M.M. Redfield, H.H. Chen, B.A. Borlaug, M.J. Semigran, K.L. Lee, and G. Lewis Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial J Am Med Assoc 309 2013 1268 1277
88. M.M. Redfield, S.J. Jacobsen, J.C. Burnett Jr., D.W. Mahoney, K.R. Bailey, and R.J. Rodeheffer Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic J Am Med Assoc 289 2003 194 202
89. 2+-regulatory site of bovine cardiac troponin J Biol Chem 257 1982 260 263
90. L.M. Ruilope, A. Dukat, M. Bohm, Y. Lacourciere, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
91. R.V. Shah, A.S. Desai, and M.M. Givertz The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis J Card Fail 16 2010 260 267
92. A.M. Shah, S.H. Shin, M. Takeuchi, H. Skali, A.S. Desai, and L. Kober Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren Eur J Heart Fail 14 2012 185 192
93. G.A. Silberman, T.H. Fan, H. Liu, Z. Jiao, H.D. Xiao, and J.D. Lovelock Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction Circulation 121 2010 519 528
94. C.S. Smith, P.A. Bottomley, S.P. Schulman, G. Gerstenblith, and R.G. Weiss Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium Circulation 114 2006 1151 1158
95. S.D. Solomon, E. Appelbaum, W.J. Manning, A. Verma, T. Berglund, and V. Lukashevich Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 2009 530 537
96. S.D. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, and E. Kraigher-Krainer The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
97. Y. Song, J.C. Shryock, S. Wagner, L.S. Maier, and L. Belardinelli Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction J Pharmacol Exp Ther 318 2006 214 222
98. S. Sossalla, and L.S. Maier Role of ranolazine in angina, heart failure, arrhythmias, and diabetes Pharmacol Ther 133 2012 311 323
99. S. Sossalla, U. Maurer, H. Schotola, N. Hartmann, M. Didie, and W.H. Zimmermann Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIdelta(C) can be reversed by inhibition of late Na(+) current Basic Res Cardiol 106 2011 263 272
100. E.J. Tsai, and D.A. Kass Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics Pharmacol Ther 122 2009 216 238
101. C. Tschope, M. Kasner, D. Westermann, R. Gaub, W.C. Poller, and H.P. Schultheiss The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements Eur Heart J 26 2005 2277 2284
102. R.W. van der Meer, L.J. Rijzewijk, H.W. de Jong, H.J. Lamb, M. Lubberink, and J.A. Romijn Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus Circulation 119 2009 2069 2077
103. L. van Heerebeek, A. Borbely, H.W. Niessen, J.G. Bronzwaer, J. van der Velden, and G.J. Stienen Myocardial structure and function differ in systolic and diastolic heart failure Circulation 113 2006 1966 1973
104. L. van Heerebeek, N. Hamdani, I. Falcao-Pires, A.F. Leite-Moreira, M.P. Begieneman, and J.G. Bronzwaer Low myocardial protein kinase G activity in heart failure with preserved ejection fraction Circulation 126 2012 830 839
105. J. Vasquez-Vivar, P. Martasek, J. Whitsett, J. Joseph, and B. Kalyanaraman The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study Biochem J 362 2002 733 739
106. H. von Bibra, M. Diamant, P.G. Scheffer, T. Siegmund, and P.M. Schumm-Draeger Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease Diab Vasc Dis Res 5 2008 310 318
107. K.T. Weber, C.G. Brilla, and J.S. Janicki Myocardial fibrosis: functional significance and regulatory factors Cardiovasc Res 27 1993 341 348
108. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett 358 1995 219 224
109. R.M. Witteles, and M.B. Fowler Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options J Am Coll Cardiol 51 2008 93 102
110. R.M. Witteles, K.V. Keu, A. Quon, H. Tavana, and M.B. Fowler Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy J Card Fail 18 2012 804 809
111. + current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction J Pharmacol Exp Ther 330 2009 550 557
112. L. Yang, G. Liu, S.I. Zakharov, A.M. Bellinger, M. Mongillo, and S.O. Marx Protein kinase G phosphorylates Cav1.2 alpha1c and beta2 subunits Circ Res 101 2007 465 474
113. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, and J.J. McMurray Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
114. F. Zannad, B. Dousset, and F. Alla Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship Hypertension 38 2001 1227 1232
115. O. Zeitz, A.E. Maass, P. Van Nguyen, G. Hensmann, H. Kogler, and K. Moller Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange Circ Res 90 2002 988 995
116. M. Zhang, N. Koitabashi, T. Nagayama, R. Rambaran, N. Feng, and E. Takimoto Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes Cell Signal 20 2008 2231 2236
117. R. Zhang, J. Zhao, A. Mandveno, and J.D. Potter Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation Circ Res 76 1995 1028 1035
118. M.R. Zile, C.F. Baicu, and W.H. Gaasch Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle N Engl J Med 350 2004 1953 1959
119. S. Zissimopoulos, N. Docrat, and F.A. Lai Redox sensitivity of the ryanodine receptor interaction with FK506-binding protein J Biol Chem 282 2007 6976 6983